Andere Sprachen UroGen Pharma Ltd.

Aktien

A2DTCV

IL0011407140

URGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:01 31.05.2024			% 5 Tage	% 1. Jan.
13,31 ^USD	-1,77 %		+0,53 %	-11,27 %

14.05.	UROGEN PHARMA LTD. : Bewertung von Oppenheimer zum Kaufen erhalten	ZM
13.05.	Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

UROGEN PHARMA LTD. : Opinion positive de Oppenheimer	14.05.
Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024	13.05.
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07.05.
UroGen Pharma Ltd. Reports on New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	05.05.
UroGen Pharma Ltd. Reports New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer	04.05.
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	15.04.
UROGEN PHARMA LTD. : Oppenheimer maintient sa recommandation à l'achat	15.03.
Transcript : UroGen Pharma Ltd., Q4 2023 Earnings Call, Mar 14, 2024	14.03.
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug	24.01.
UROGEN PHARMA LTD. : Opinion positive de Oppenheimer	24.01.
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	24.01.
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	17.01.
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	17.01.
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise	17.01.
UROGEN PHARMA LTD. : Oppenheimer optimiste sur le dossier	15.11.
Transcript : UroGen Pharma Ltd., Q3 2023 Earnings Call, Nov 14, 2023	14.11.
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen UroGen Pharma Ltd.

Aktien

A2DTCV

IL0011407140

URGN

Andere Sprachen

Filter